India Attracts MNC Drug Makers As Vaccine Market Growth Sector
This article was originally published in PharmAsia News
Executive Summary
India is fast becoming attractive to multinational pharmaceutical companies as a place to market vaccines, once relegated to the back burner as among the less-profitable of product lines. GlaxoSmithKline, Novartis and Pfizer are looking at the market potential in India as they see vaccines as one of the more profitable segments of their drug lines. Vaccine sales in India are projected to grow at an annual rate of at least 16 percent, soon becoming a $1 billion market. Three-fifths of the vaccine market in India is pediatric. (Click here for more